Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.

Marc A PfefferBrian ClaggettEldrin F LewisChristopher B GrangerLars KøberAldo Pietro MaggioniDouglas L MannJohn Joseph Valentine McMurrayJean-Lucien RouleauScott D SolomonPhillippe Gabriel StegOtavio BerwangerMaja CikesCarmine G De PasqualeCara EastAlberto FernandezKarola JeringUlf LandmesserRoxana MehranBéla MerkelyFreny Vaghaiwalla ModyMark C PetrieIvo PetrovMorten SchouMichele SenniDavid SimPeter van der MeerMartin LefkowitzYinong ZhouJianjian GongEugene Braunwaldnull null

Published in: The New England journal of medicine (2021)

Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis; PARADISE-MI ClinicalTrials.gov number, NCT02924727.).

Keyphrases

acute myocardial infarction
heart failure
left ventricular
percutaneous coronary intervention
cardiovascular disease
risk factors
angiotensin ii
ejection fraction
angiotensin converting enzyme
cardiac resynchronization therapy
coronary artery disease
acute coronary syndrome
type diabetes
binding protein